(Q34806513)

4 August 2017

1 reference

title

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection (English)

1 reference

4 August 2017

Sharon S Lieberman-Blum

series ordinal

1

1 reference

PubMed ID

18691983

4 August 2017

Horatio B Fung

series ordinal

2

1 reference

PubMed ID

18691983

4 August 2017

Juan C Bandres

series ordinal

3

1 reference

4 August 2017

1 July 2008

1 reference

4 August 2017

Clinical Therapeutics

1 reference

4 August 2017

30

1 reference

4 August 2017

7

1 reference

4 August 2017

1228-1250

1 reference

4 August 2017

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

A new classification for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Association between CCR5 genotype and the clinical course of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

The entry of entry inhibitors: a fusion of science and medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

HIV-1 cell entry and advances in viral entry inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

The potential for HIV fusion inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

The plasma membrane as a combat zone in the HIV battlefield

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Access denied? The status of co-receptor inhibition to counter HIV entry

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

O425 Efficacy and safety of maraviroc in treatment-experienced (TE) patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

The clinical pharmacology of antiretrovirals in development

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980048-3

7 January 2021

10.1016/S0149-2918(08)80048-3

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

18691983